These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22483770)

  • 1. [The stakes of pre- and post-market authorization development and clinical assessment].
    Schwebig A
    Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
    [No Abstract]   [Full Text] [Related]  

  • 2. Ethical considerations in orphan drug approval and use.
    Kesselheim AS
    Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis to guide orphan drug development.
    Lesko LJ
    Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cohorts and registers: Which public/private partnerships to choose?].
    Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
    Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
    [No Abstract]   [Full Text] [Related]  

  • 5. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug labels: a flawed source of data for studying orphan drug approvals.
    Kesselheim AS; Avorn J
    Clin Pharmacol Ther; 2012 Dec; 92(6):694; author reply 695. PubMed ID: 23073207
    [No Abstract]   [Full Text] [Related]  

  • 7. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical devices on trial, Part I.
    Wright D
    Med Device Technol; 2002 Dec; 13(10):35-8. PubMed ID: 12575529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 10. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 11. [Going from research to development: which support and financing tools?].
    Roques S
    Presse Med; 2012 May; 41 Suppl 1():S43-5. PubMed ID: 22465719
    [No Abstract]   [Full Text] [Related]  

  • 12. Providing Quality Therapeutics in Switzerland: Role of the Stakeholders and Recent Incentives for Further Improvements.
    Besson M; Samer C; Rollason V; Dayer P; Desmeules J
    Clin Ther; 2015 Jul; 37(7):1588-92. PubMed ID: 26049714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
    Tremaine WJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials.
    French JA
    Epilepsia; 2002 Sep; 43(9):951-5. PubMed ID: 12199719
    [No Abstract]   [Full Text] [Related]  

  • 15. Rare lung disease and orphan drug development.
    Spagnolo P; du Bois RM; Cottin V
    Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Don't Do Different Things…Do Things Differently! Drug Development in Rare Diseases.
    Rudek MA; Korth-Bradley JM
    Clin Pharmacol Ther; 2016 Oct; 100(4):333-5. PubMed ID: 27393720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerating access to treatments for rare diseases.
    Dunoyer M
    Nat Rev Drug Discov; 2011 Jun; 10(7):475-6. PubMed ID: 21701499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating orphan drug development.
    Coté TR; Xu K; Pariser AR
    Nat Rev Drug Discov; 2010 Dec; 9(12):901-2. PubMed ID: 21119719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priorities for the Priority Review Voucher.
    Ridley DB
    Am J Trop Med Hyg; 2017 Jan; 96(1):14-15. PubMed ID: 27573624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.